# AMT-562 in Patients With Selected Advanced Solid Tumors

> **NCT06199908** · PHASE1 · UNKNOWN · sponsor: **Multitude Therapeutics (Australia) Pty Ltd** · enrollment: 72 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** AMT-562

## Key facts

- **NCT ID:** NCT06199908
- **Lead sponsor:** Multitude Therapeutics (Australia) Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-05-20
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2024-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06199908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06199908, "AMT-562 in Patients With Selected Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06199908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*